Blood Marker Determines Response To Colorectal Cancer Drug

Extracting DNA from glass slides (some over a decade old) yielded highly variable success; thus, only DNAs obtained from cores were analyzed. DNA was extracted using the QIAamp FFPE DNA Kit (Qiagen, Hilden, Germany). DNA quantity (spectrophotometry) and quality (polymerase chain reactions) were checked. DNA was genotyped blindly by Transgenomic, Inc (New Haven, CT, USA) using Sanger sequencing.

Geoffrey Liu, MD, a senior scientists and lead author said, “Our study discovered that the blood marker Fc-γ receptor FCGR2A identifies a new group of patients that will benefit from taking cetuximab. With this finding, we believe we are now on the way to move it into the clinical setting to provide patients targeted, effective treatment. Our finding, which resulted from analyzing archived tumor and normal tissue samples from some of the 572 patients enrolled in that trial, further refines this quest and defines another subset of patients who will respond to the drug. So instead of looking at aspects in the tumors, which is where RAS mutations show up, we looked at certain things in the blood and normal tissues that we could measure for heritable genetic variations.” The study was published on May 15, 2016, in the journal Clinical Cancer Research.

Related Links:
Princess Margaret Cancer Centre
Qiagen
Transgenomic